Loading market dashboard
Wag! Group Co.
PETTechnologyNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
As theranostics adoption acceleratesi and radiopharmaceutical demand grows,ii healthcare systems are under increasing pressure to scale nuclear medicine operat
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic lateral sclerosis (ALS) Previously reported data also showed detection of TDP-43 in patients with genetically defined frontotemporal dementia (FTD) Underlines potential for precision medicine enabling early diagnosis and intervention in multiple neurodegenerative diseases Lausanne, Switzerland, May 22, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the presentation of new preliminary data from a Phase 1 trial of its first-in-class TDP-43 positron emission tomography (PET) tracer ACI-19626 showing increased uptake in the brains of patients with amyotrophic lateral sclerosis (ALS). The results presented at the 2026 TDP43 Summit in Madison, Wisconsin, demonstrate that PET scans with ACI-19626 showed tracer uptake significantly higher in key regions of the brain in patients with ALS compared to healthy controls.
VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with Catalyst MedTech (Catalyst), to provide a minimum of 200 brain Positron Emission Tomography (PET) scans for an upcoming Alzheimer's Disease (AD) clinical trial, to be conducted by an international Contract Research Organization (CRO) specializing in AD research. The PET Scans will be performed at the Company's NovaScan Neuroimaging Clinics™ second location planned for Tampa, Florida.
MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies developing advanced minimally invasive and image-guided treatment ablative technologies for prostate cancer, including focal, subtotal, and whole-gland treatment approaches. These initiatives reflect Telix's commitment to advancing the integration of molecular imaging into the evolving prostate cancer treatment landscape to help inform clinical decision-making.
MARKHAM, Ontario, May 12, 2026 (GLOBE NEWSWIRE) -- Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET) announced at its Annual General Meeting of Shareholders (the “Meeting”) held today that all of the director nominees set out in the Company's Management Information Circular dated March 17, 2026, were elected as directors of Pet Valu.
Pet Valu Holdings Ltd. (PET:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Pet Valu Holdings Ltd. (PET:CA) Q1 2026 Earnings Call Transcript
MARKHAM, Ontario, May 12, 2026 (GLOBE NEWSWIRE) -- Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET), the leading Canadian specialty retailer of pet food and pet-related supplies, today announced its financial results for the first quarter 2026.
BERLIN & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced positive topline results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women's Hospital that evaluated the investigational PET/CT radiotracer I 124 evuzamitide.1,5 The study met the primary endpoints of sensitivity (the ability of a test to identify individuals who have the condition) and specificity (the ability of a test to identify individuals who do not have the condition) for the diagnosis of.
MARKHAM, Ontario, April 28, 2026 (GLOBE NEWSWIRE) -- Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET), the leading Canadian specialty retailer of pet food and pet-related supplies, will release its financial results for the first quarter of fiscal 2026 and hold its Annual General Meeting of Shareholders on Tuesday, May 12, 2026.
Algernon Health (CSE:AGN, OTCQB:AGNPF, FRA:AGW0) on Wednesday announced “NovaScan Neuroimaging Clinics” as the new brand name for its planned US network of brain PET scanning centers, with the first location set to open in Davie, Florida. The company said the clinics will feature the US Food and Drug Administration-cleared CareMiBrain system, a standalone PET scanner designed specifically for brain imaging and not integrated with computed tomography (CT).
VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to introduce NovaScan Neuroimaging ClinicsTM as the new brand name and visual identity for its planned U.S. network of brain PET scanning centers being launched at the HCA Florida University Medical Offices building in Davie, and featuring the U.S. FDA-cleared CareMiBrain™ system, a groundbreaking, standalone PET scanner without an integrated CT component. NovaScan Neuroimaging Clinics TM The new brand name and visual identity has been designed with a clean and elegant look reflective of the Company's vision for a streamlined approach to dedicated brain PET imaging, and the revolutionary technology that the Company clinics will feature.
Algernon Health (CSE:AGN, OTCQB:AGNPF, FRA:AGW0) announced that it will open its first US brain-dedicated positron emission tomography (PET) scanning clinic at the HCA Florida University Medical Office Building in Davie, on the campus of HCA Florida University Hospital. The company, through its wholly owned subsidiary Algernon USA LLC, has signed a five-year lease for the site with an option to renew for an additional five years.
VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to announce that it will be opening its inaugural brain PET (Positron Emission Tomography) scanning clinic at the HCA Florida University Medical Office Building in Davie, located on the campus of the HCA Florida University Hospital. Algernon USA LLC, a wholly owned subsidiary, has signed a five-year lease with a renewal option for an additional five-years.
WEST SACRAMENTO, Calif. & SÃO PAULO--(BUSINESS WIRE)--Origin Materials, Inc. (“Origin”) (NASDAQ: ORGN, ORGNW), a technology company with a mission to enable the world's transition to sustainable materials, announced a strategic distributor relationship with HP Embalagens, a leader in high-performance thermoformed packaging, for sustainable PET bottlecaps. HP Embalagens expects to purchase PET caps from Origin Materials for sale and distribution to its customer base, including many of the world'.
